Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor David Bennett is leading a new national research consortium to investigate neuropathic pain.

PAINSTORM (Partnership for Assessment and Investigation of Neuropathic Pain: Studies Tracking Outcomes, Risks and Mechanisms) is part of the new Advanced Pain Discovery Platform, a major investment led by the Medical Research Council and supported by the UKRI Strategic Priorities Fund and Versus Arthritis. It will involve NDCN colleagues Professor David Bennett, Professor Irene Tracey, Associate Professor Annina Schmid, Clinical Lecturer Andreas Themistocleous, Research Co-investigator Georgios Baskozos, and Project Manager Mathilde Pascal.

I believe that PAINSTORM, both due to its scale and embedded interdisciplinary interactions, can bring a perspective to neuropathic pain which has previously not been possible even on a global scale. I look forward to working with all our academic partners, industry and our patient partners, ultimately to make a positive impact on the lives of those living with neuropathic pain. - Professor David Bennett, Nuffield Department of Clinical Neurosciences

The Oxford team will be working closely with patient partners; academic colleagues in Dundee, Aberdeen, Imperial, King's College London and Ghent; and industry partners Lilly and AstraZeneca. The aim is that this inter-disciplinary collaboration will help translate the research into effective, multifaceted interventions.

Neuropathic pain has a major impact on quality of life, affecting 8% of the population. It is caused by damage to the sensory nervous system, through conditions such as diabetes, chemotherapy and HIV. Current management options are only effective in a small subgroup of patients, and much of the research and clinical management in this area is separate rather than being interdisciplinary.

PAINSTORM will use a broad range of approaches cutting across traditional disciplinary boundaries, to uncover the causes of neuropathic pain and understand how they interact, from molecule to society. The focus will be on studying people at risk of neuropathic pain and following their progress over time.

PAINSTORM will be investigating the pathophysiological mechanisms underlying neuropathic pain, improving outcome measures/pain biomarkers and ultimately translating this into better management of neuropathic pain. The team hope to improve the targeting of existing analgesics as well as identify new therapeutic targets and optimise psychological and physical interventions.

Similar stories

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.

International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic

Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.

Alexander Davies wins top UKRI Future Leaders Fellowship

Alex is one of eight Oxford University academics who have been awarded significant financial funding from the UKRI Future Leaders Fellowships Scheme

New study on link between autoimmunity and pain

Patients with autoantibodies which target neuronal proteins can have pain as an under-recognised clinical manifestation.